Aptevo Therapeutics Inc (APVO) Insider Marvin L. White Purchases 10,000 Shares
Aptevo Therapeutics Inc (NASDAQ:APVO) insider Marvin L. White bought 10,000 shares of the firm’s stock in a transaction on Tuesday, December 4th. The stock was acquired at an average cost of $2.38 per share, with a total value of $23,800.00. Following the completion of the transaction, the insider now directly owns 203,603 shares of the company’s stock, valued at $484,575.14. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.
APVO stock traded down $0.02 during trading hours on Friday, hitting $2.24. The company’s stock had a trading volume of 619 shares, compared to its average volume of 73,334. The company has a quick ratio of 3.65, a current ratio of 3.91 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $54.68 million, a price-to-earnings ratio of -1.49 and a beta of 2.06. Aptevo Therapeutics Inc has a 12 month low of $2.22 and a 12 month high of $6.35.
Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Wednesday, November 14th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.01. Aptevo Therapeutics had a negative net margin of 252.44% and a negative return on equity of 78.85%. The business had revenue of $5.82 million during the quarter, compared to analysts’ expectations of $6.87 million. On average, research analysts expect that Aptevo Therapeutics Inc will post -2.31 EPS for the current fiscal year.
Several research firms have commented on APVO. Zacks Investment Research raised shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a research report on Tuesday, August 14th. ValuEngine raised shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, August 13th. Piper Jaffray Companies reissued an “overweight” rating and issued a $11.00 target price on shares of Aptevo Therapeutics in a research report on Friday, August 10th. LADENBURG THALM/SH SH began coverage on shares of Aptevo Therapeutics in a research report on Monday, November 5th. They issued a “buy” rating and a $14.00 target price for the company. Finally, Roth Capital set a $12.00 target price on shares of Aptevo Therapeutics and gave the stock a “buy” rating in a research report on Thursday, November 15th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $10.69.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/aptevo-therapeutics-inc-apvo-insider-marvin-l-white-purchases-10000-shares/2668119.html.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Featured Story: Do closed-end mutual funds pay dividends?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.